ClaimsFiler Reminds Investors of Soleno Therapeutics Securities Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SLNO?
Source: Globenewswire
- Lawsuit Deadline: ClaimsFiler reminds investors of Soleno Therapeutics (Nasdaq: SLNO) that they must file lead plaintiff applications by May 5, 2026, for shares purchased between March 26, 2025, and November 4, 2025, highlighting investor concerns over potential legal risks associated with the company.
- Legal Allegations Overview: Soleno and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, specifically regarding undisclosed safety concerns related to its only commercial product, DCCR, which could expose investors to greater financial losses.
- Insufficient Safety Disclosure: The lawsuit claims that the clinical trials for DCCR did not adequately disclose potential safety issues, including excessive fluid retention among participants, which could adversely affect the drug's market acceptance and the company's reputation.
- Commercial Viability Risks: Due to undisclosed safety risks, the commercial viability of DCCR is questioned, potentially leading to increased patient discontinuation rates, reduced prescriber willingness, and possible regulatory and legal repercussions, further impacting the company's financial performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.780
Low
75.00
Averages
110.50
High
125.00
Current: 52.780
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its first commercial product, VYKAT XR (diazoxide choline) extended-release tablets, is a once-daily oral treatment for hyperphagia in adults and children four years of age and older with Prader-Willi syndrome (PWS). VYKAT XR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. The KATP channels play a central role in the regulation of a number of physiological processes which may otherwise be dysregulated, contributing to the pathophysiology of several diseases. In the context of the underlying genetic or structural defects in PWS, these pathophysiological processes may cumulatively contribute to increases in appetite and aggressive food seeking, lack of satiety, accumulation of excess body fat and the establishment and perpetuation of the obese state. PWS is a rare, complex genetic neurobehavioral/metabolic disorder.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ClaimsFiler Reminds Investors of Soleno Therapeutics Securities Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds investors of Soleno Therapeutics (Nasdaq: SLNO) that they must file lead plaintiff applications by May 5, 2026, for shares purchased between March 26, 2025, and November 4, 2025, highlighting investor concerns over potential legal risks associated with the company.
- Legal Allegations Overview: Soleno and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, specifically regarding undisclosed safety concerns related to its only commercial product, DCCR, which could expose investors to greater financial losses.
- Insufficient Safety Disclosure: The lawsuit claims that the clinical trials for DCCR did not adequately disclose potential safety issues, including excessive fluid retention among participants, which could adversely affect the drug's market acceptance and the company's reputation.
- Commercial Viability Risks: Due to undisclosed safety risks, the commercial viability of DCCR is questioned, potentially leading to increased patient discontinuation rates, reduced prescriber willingness, and possible regulatory and legal repercussions, further impacting the company's financial performance.
See More
Faruqi & Faruqi Encourages Soleno Investors to Reach Out
- Legal Investigation: Faruq & Faruq LLP is investigating potential claims against Soleno Therapeutics, Inc. for securities purchased between March 26, 2025, and November 4, 2025, indicating possible legal risks for the company that investors should be aware of.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Investors who have suffered losses can contact Faruq & Faruq partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, ensuring they receive professional guidance.
- Market Impact: As the legal investigation unfolds, Soleno's stock price may face negative pressure, prompting investors to monitor developments closely to adjust their investment strategies and mitigate potential losses.
See More
Soleno Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Soleno Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 26, 2025, and November 4, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Allegation: The complaint alleges that Soleno misrepresented safety concerns related to its DCCR drug during Phase 3 clinical trials, rendering its public statements false and misleading, which resulted in investor losses when the truth emerged.
- Increased Safety Risks: Soleno's DCCR treatment exhibited greater safety risks than disclosed, alongside lower commercial viability and heightened adverse event risks, severely undermining investor confidence and leading to significant financial repercussions.
- Legal Consequences and Investor Rights: Until the class action is certified, investors are not represented by an attorney; the Schall Law Firm offers free consultations to help investors understand their rights and pursue recovery of losses.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the lead plaintiff deadline for the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO) on May 5, 2026, urging affected investors to submit their losses before this date to participate in the lawsuit.
- Concealed Safety Risks: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, resulting in significant losses for investors who relied on these assurances.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 financial results, admitting disruptions in DCCR's launch trajectory, which led to a 27% drop in stock price in a single day, indicating severe market concerns about the company's future.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, thereby aiding the investigation into Soleno's practices.
See More
Soleno Therapeutics Shareholder Alert
- FDA Approval and Safety Claims: Soleno received FDA approval for its sole commercial product, VYKAT XR, on March 26, 2025, claiming a 'well-established safety profile,' yet the lawsuit alleges concealment of serious adverse effects like fluid retention and metabolic risks.
- Financial Reporting and Market Confidence: In its Q1 report on May 7, 2025, Soleno stated there was a 'high level of interest' in the drug and claimed the company was 'very well positioned to sustain our current momentum,' but these statements are alleged to be materially incomplete regarding safety information.
- Minimization of Risks at Conference: During the Goldman Sachs Global Healthcare Conference on June 10, 2025, Soleno's CFO claimed only two severe adverse events in the clinical program, further downplaying risks, while the lawsuit contends these risks were significantly underestimated.
- Denial of Safety Signals and Report Release: On August 6, 2025, Soleno reported $32.7 million in DCCR revenue and claimed no new safety signals, but a report from Scorpion Capital revealed high risks associated with the drug, questioning the reliability of clinical trial data.
See More
Reminder of Securities Fraud Class Action Against Soleno Therapeutics, Inc.
- Lawsuit Background: Soleno Therapeutics, Inc. faces a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with plaintiffs being investors who purchased shares between March 26, 2025, and August 4, 2025, claiming misrepresentations regarding the company's Phase 3 clinical trial for DCCR, which may have led to investor losses.
- Investor Action: Investors must file papers by May 5, 2026, to serve as lead plaintiffs in the class action, representing other members in the litigation, although those who choose not to participate can still share in any recovery.
- Legal Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to take action.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List,” demonstrating its strong capabilities and reputation in protecting investor rights.
See More
ClaimsFiler Reminds Investors of Soleno Therapeutics Securities Lawsuit
- Lawsuit Deadline: ClaimsFiler reminds investors of Soleno Therapeutics (Nasdaq: SLNO) that they must file lead plaintiff applications by May 5, 2026, for shares purchased between March 26, 2025, and November 4, 2025, highlighting investor concerns over potential legal risks associated with the company.
- Legal Allegations Overview: Soleno and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, specifically regarding undisclosed safety concerns related to its only commercial product, DCCR, which could expose investors to greater financial losses.
- Insufficient Safety Disclosure: The lawsuit claims that the clinical trials for DCCR did not adequately disclose potential safety issues, including excessive fluid retention among participants, which could adversely affect the drug's market acceptance and the company's reputation.
- Commercial Viability Risks: Due to undisclosed safety risks, the commercial viability of DCCR is questioned, potentially leading to increased patient discontinuation rates, reduced prescriber willingness, and possible regulatory and legal repercussions, further impacting the company's financial performance.
See More
Faruqi & Faruqi Encourages Soleno Investors to Reach Out
- Legal Investigation: Faruq & Faruq LLP is investigating potential claims against Soleno Therapeutics, Inc. for securities purchased between March 26, 2025, and November 4, 2025, indicating possible legal risks for the company that investors should be aware of.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, emphasizing the importance of timely action to protect their rights.
- Direct Contact Channels: Investors who have suffered losses can contact Faruq & Faruq partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, ensuring they receive professional guidance.
- Market Impact: As the legal investigation unfolds, Soleno's stock price may face negative pressure, prompting investors to monitor developments closely to adjust their investment strategies and mitigate potential losses.
See More
Soleno Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against Soleno Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between March 26, 2025, and November 4, 2025, with a deadline to contact the firm by May 5, 2026.
- False Statements Allegation: The complaint alleges that Soleno misrepresented safety concerns related to its DCCR drug during Phase 3 clinical trials, rendering its public statements false and misleading, which resulted in investor losses when the truth emerged.
- Increased Safety Risks: Soleno's DCCR treatment exhibited greater safety risks than disclosed, alongside lower commercial viability and heightened adverse event risks, severely undermining investor confidence and leading to significant financial repercussions.
- Legal Consequences and Investor Rights: Until the class action is certified, investors are not represented by an attorney; the Schall Law Firm offers free consultations to help investors understand their rights and pursue recovery of losses.
See More
Soleno Therapeutics Securities Class Action Reminder
- Lawsuit Background: Hagens Berman reminds investors of the lead plaintiff deadline for the pending securities class action against Soleno Therapeutics (NASDAQ:SLNO) on May 5, 2026, urging affected investors to submit their losses before this date to participate in the lawsuit.
- Concealed Safety Risks: The lawsuit alleges that Soleno misrepresented the safety and commercial viability of its flagship product, VYKAT™ XR (DCCR), for treating Prader-Willi syndrome, resulting in significant losses for investors who relied on these assurances.
- Stock Price Plunge: On November 4, 2025, Soleno reported Q3 financial results, admitting disruptions in DCCR's launch trajectory, which led to a 27% drop in stock price in a single day, indicating severe market concerns about the company's future.
- Whistleblower Program: Hagens Berman encourages individuals with non-public information to consider the SEC Whistleblower program, which offers rewards of up to 30% of any successful recovery, thereby aiding the investigation into Soleno's practices.
See More
Soleno Therapeutics Shareholder Alert
- FDA Approval and Safety Claims: Soleno received FDA approval for its sole commercial product, VYKAT XR, on March 26, 2025, claiming a 'well-established safety profile,' yet the lawsuit alleges concealment of serious adverse effects like fluid retention and metabolic risks.
- Financial Reporting and Market Confidence: In its Q1 report on May 7, 2025, Soleno stated there was a 'high level of interest' in the drug and claimed the company was 'very well positioned to sustain our current momentum,' but these statements are alleged to be materially incomplete regarding safety information.
- Minimization of Risks at Conference: During the Goldman Sachs Global Healthcare Conference on June 10, 2025, Soleno's CFO claimed only two severe adverse events in the clinical program, further downplaying risks, while the lawsuit contends these risks were significantly underestimated.
- Denial of Safety Signals and Report Release: On August 6, 2025, Soleno reported $32.7 million in DCCR revenue and claimed no new safety signals, but a report from Scorpion Capital revealed high risks associated with the drug, questioning the reliability of clinical trial data.
See More
Reminder of Securities Fraud Class Action Against Soleno Therapeutics, Inc.
- Lawsuit Background: Soleno Therapeutics, Inc. faces a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with plaintiffs being investors who purchased shares between March 26, 2025, and August 4, 2025, claiming misrepresentations regarding the company's Phase 3 clinical trial for DCCR, which may have led to investor losses.
- Investor Action: Investors must file papers by May 5, 2026, to serve as lead plaintiffs in the class action, representing other members in the litigation, although those who choose not to participate can still share in any recovery.
- Legal Fee Arrangement: All representation is on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages more affected shareholders to take action.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List,” demonstrating its strong capabilities and reputation in protecting investor rights.
See More
